Progression-Free Survival Up to 1 Year [clinicaltrials_resource:692307510f567400856429875d86a58e]
Median number of months before disease progressed in patient on gemcitabine when treated with the combination of panobinostat and bortezomib. Progression free survival is measured from randomization until the subject has documented disease progression by an objective measure. Subjects must be alive with no more than 20% increase in tumor size to qualify for progression free survival. Changes in tumor size are defined by RECIST criteria.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Progression-Free Survival Up to 1 Year [clinicaltrials_resource:692307510f567400856429875d86a58e]
Median number of months before disease progressed in patient on gemcitabine when treated with the combination of panobinostat and bortezomib. Progression free survival is measured from randomization until the subject has documented disease progression by an objective measure. Subjects must be alive with no more than 20% increase in tumor size to qualify for progression free survival. Changes in tumor size are defined by RECIST criteria.
Bio2RDF identifier
692307510f567400856429875d86a58e
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:692307510f567400856429875d86a58e
measure [clinicaltrials_vocabulary:measure]
Progression-Free Survival
time frame [clinicaltrials_vocabulary:time-frame]
Up to 1 Year
description
Median number of months before ...... re defined by RECIST criteria.
identifier
clinicaltrials_resource:692307510f567400856429875d86a58e
title
Progression-Free Survival Up to 1 Year
@en
type
label
Progression-Free Survival Up t ...... 307510f567400856429875d86a58e]
@en